Pitt Shield

Noninvasive and transient blood-brain barrier opening in the hippocampus of Alzheimer's double transgenic mice using focused ultrasound.

Authors: Choi JJ, Wang S, Brown TR, Small SA, Duff KE, Konofagou EE

The spatio-temporal nature of focused ultrasound-induced blood-brain barrier (BBB) opening as a brain drug delivery method was investigated in Alzheimer's disease model mice. The left hippocampus of transgenic (APP/PS1, n = 3) and nontransgenic (n = 3) mice was sonicated (frequency: 1.525 MHz, peak-negative pressure: 600 kPa, pulse length: 20 ms, duty cycle: 20%, duration: 1 min) in vivo, through their intact skin and skull, after intravenous injection of microbubbles (SonoVue; 25 microl). Sequential, high-field MR images (9.4 Tesla) were acquired before and after injection of gadolinium (Omniscan, 0.75 ml, molecular weight: 573.7 Da) on two separate days for each mouse. Gadolinium deposits through the ultrasound-induced BBB opening in the left hippocampus revealed significant contrast-enhancement in the MRI. On the following day, MRI revealed significant BBB closure within the same region. However, the BBB opening extent and BBB closing timeline varied in different regions within the same sonicated location. This indicates that opening and closing were dependent on the brain region targeted. No significant difference in BBB opening or closing behaviors was observed between the APP/PS1 and the nontransgenic mice. In conclusion, a BBB-impermeable molecule was noninvasively, transiently and reproducibly delivered to the hippocampus of Alzheimer's APP/PS1 mice.

Introduction

Purpose Drug delivery with BBB opening
Study Objective To investigate the spatio-temporal characteristics of focused ultrasound-induced blood–brain barrier opening and closure for delivery of a BBB-impermeable molecule to the hippocampus in an Alzheimer's disease mouse model.
Animal model / Human subject Mouse (Mus musculus), transgenic APP/PS1 and nontransgenic controls; age None; sex None.
Disease model Alzheimer's disease (APP/PS1 transgenic mouse model)
MRI or image guidance method Left hippocampus was targeted for sonication; localization and assessment were performed using sequential high-field (9.4 T) contrast-enhanced MRI with gadolinium to confirm BBB opening. No stereotactic apparatus or explicit real-time MRI guidance during sonication was reported.
Targeted brain region(s) Hippocampus
Target coordinates None in text
Cargo name and characteristics Gadolinium-based small-molecule MRI contrast agent (Omniscan™; gadodiamide), molecular weight ~573.7 Da, BBB‑impermeable chelate used for contrast enhancement
Route of administration Intravenous (microbubbles and gadolinium were injected IV; cargo delivered to the hippocampus via focused ultrasound-induced transient BBB opening)

Outcomes and Safety

Summary of Outcomes Focused ultrasound noninvasively, transiently, and reproducibly opened the blood–brain barrier in the mouse hippocampus to allow delivery of a normally impermeable molecule (gadolinium), with region-dependent opening/closing kinetics and no differences between APP/PS1 and nontransgenic mice.
Duration of biological effect 1 day
Safety-related matter No safety issues or adverse effects are mentioned; the authors describe the BBB opening as noninvasive, transient, and reproducible.

Brain Region

Ultrasound Parameters

Ultrasound instrument None (no system name or manufacturer given). Reported sonication parameters: frequency 1.525 MHz; peak-negative pressure 600 kPa; pulse length 20 ms; duty cycle 20%; duration 1 min. No transducer aperture or diameter reported.
FUS Frequency 1.525 MHz
FUS Intensity Spatial-peak pulse-average intensity (Isppa) ≈ 12 W/cm2; Spatial-peak temporal-average intensity (Ispta) ≈ 2.4 W/cm2
FUS Pressure 0.600 MPa (peak-negative)
FUS Mode pulsed
Pulse duration 20 ms
Duration of a single FUS session 1 min
Focal Characteristics None in the paper
Treatment frequency single session

We are open to feedback. If you see a mistake or have a suggestion, please contact us.

← Back to Search